NervGen Pharma Management
Management criteria checks 2/4
NervGen Pharma's CEO is Mike Kelly, appointed in Apr 2023, has a tenure of 1.67 years. total yearly compensation is CA$740.33K, comprised of 72.9% salary and 27.1% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $300.52K. The average tenure of the management team and the board of directors is 1.7 years and 3.9 years respectively.
Key information
Mike Kelly
Chief executive officer
CA$740.3k
Total compensation
| CEO salary percentage | 72.9% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.7yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CA$24m |
| Jun 30 2024 | n/a | n/a | -CA$23m |
| Mar 31 2024 | n/a | n/a | -CA$20m |
| Dec 31 2023 | CA$740k | CA$540k | -CA$22m |
Compensation vs Market: Mike's total compensation ($USD515.17K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.
CEO
Mike Kelly (58 yo)
1.7yrs
Tenure
CA$740,330
Compensation
Mr. Michael Kelly, also known as Mike, is an Independent Director of ARS Pharmaceuticals, Inc. and joined in May 2019. He serves as Chief Executive Officer, President and Director of NervGen Pharma Corp. s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.7yrs | CA$740.33k | 0.20% $ 300.5k | |
| Co-Founder & Advisor | no data | CA$60.00k | no data | |
| Co-Founder & Independent Director | no data | no data | 1.6% $ 2.3m | |
| CFO & Corporate Secretary | 4.8yrs | CA$431.63k | 0.22% $ 325.3k | |
| Chief Medical Officer | 3.6yrs | CA$793.99k | no data | |
| Co-Founder & Advisor | no data | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data | |
| Senior Vice President of Program Management | less than a year | no data | no data |
1.7yrs
Average Tenure
61.5yo
Average Age
Experienced Management: NGEN.F's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.7yrs | CA$740.33k | 0.20% $ 300.5k | |
| Co-Founder & Independent Director | 7.9yrs | no data | 1.6% $ 2.3m | |
| Co-Founder & Advisor | no data | no data | no data | |
| Chairman | 3.3yrs | no data | 0.083% $ 122.1k | |
| Independent Director | 6.6yrs | no data | 0.57% $ 835.0k | |
| Independent Director | 4.2yrs | no data | 0.014% $ 20.9k | |
| Member of Alzheimer's Disease Scientific Advisory Board | 3.9yrs | no data | no data | |
| Co-Inventor & Scientific Advisor | no data | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 3.9yrs | no data | no data | |
| Advisor | 4.2yrs | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 3.9yrs | no data | no data |
3.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: NGEN.F's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 16:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NervGen Pharma Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chelsea Stellick | iA Capital Markets |
| Scott McAuley | Paradigm Capital, Inc. |
| Justin Keywood | Stifel Canada |